Added to YB: 2026-02-10
Pitch date: 2026-02-06
MLTX [neutral]
MoonLake Immunotherapeutics
+17.23%
current return
Author Info
Clinical Catalysts breaks down the science and strategy behind pharma market movers. Sign up for the newsletter.
Company Info
MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases.
Market Cap
$1.1B
Pitch Price
$15.50
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.57
P/E
-4.66
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Biotech Catalysts on My Radar | February 2026 - MoonLake Immunotherapeutics
MLTX (quick overview): Biotech developing sonelokimab, dual IL-17A/F inhibitor for axial spondyloarthritis. Phase 2 S-OLARIS data readout Feb 23, 2026 measuring spinal inflammation reduction via PET/MRI in 25-26 patients over 12 weeks. Positive data could validate differentiated mechanism vs existing biologics and justify advancement to pivotal trials. Risk: inconclusive results question deep tissue efficacy.
Read full article (2 min)